PMID- 34609337
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20230927
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
VI  - 28
IP  - 2
DP  - 2022 Mar 1
TI  - A Medical Records Review Study Assessing Safety of Zoster Vaccine Recombinant, 
      Adjuvanted in Patients With Rheumatic Disease.
PG  - e528-e531
LID - 10.1097/RHU.0000000000001790 [doi]
AB  - OBJECTIVE: Patients with rheumatic disease are at increased risk for herpes 
      zoster infection. Because of limited safety data in this population and concerns 
      over vaccine-precipitated flares, there are no guidelines for vaccination with 
      the zoster vaccine recombinant, adjuvanted (ZRA). We evaluated self-reported 
      adverse events (AEs) and disease activity after ZRA administration in adults with 
      rheumatic disease. METHODS: In this medical records review study at our large 
      academic center, patients who had received at least 1 dose of ZRA from January 1, 
      2018 to March 11, 2020 were assessed. Self-reported AEs and disease activity were 
      monitored 3 months after each ZRA administration. Measures of disease activity 
      were reviewed 6 months before ZRA in those who received both doses, or 3 months 
      before ZRA in those who received 1 dose. RESULTS: We identified 65 patients, of 
      whom 34 (52.3%) received both doses of ZRA. Four patients (6.2%) self-reported 
      AEs after receiving ZRA, all of which were minor and systemic. Three patients 
      (9.2%) developed a flare after receiving ZRA, compared with 8 (12.3%) who 
      experienced a flare in the baseline period. There was no significant change in 
      flare incidence or disease activity after vaccination. Subgroup analysis of those 
      on biologic and nonbiologic disease-modifying antirheumatic drugs revealed no 
      differences in frequency of postvaccination AEs, flares, or disease activity. 
      CONCLUSIONS: In our cohort, disease activity seemed stable when comparing disease 
      markers before and after ZRA administration. In addition, ZRA was well-tolerated 
      with minor AEs. Further studies are needed to guide formal vaccination 
      recommendations.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Gupta, Surbhi
AU  - Gupta S
AD  - From the Department of Rheumatic Diseases, University of California, Los Angeles, 
      Los Angeles, CA.
FAU - Arasaratnam, Reuben J
AU  - Arasaratnam RJ
AD  - Divisions of Infectious Diseases and Geographic Medicine.
FAU - Solow, E Blair
AU  - Solow EB
AD  - Rheumatic Diseases, Department of Internal Medicine, University of Texas 
      Southwestern Medical Center, Dallas TX.
FAU - Bajaj, Puneet
AU  - Bajaj P
AD  - Rheumatic Diseases, Department of Internal Medicine, University of Texas 
      Southwestern Medical Center, Dallas TX.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
RN  - 0 (Adjuvants, Vaccine)
RN  - 0 (Herpes Zoster Vaccine)
SB  - IM
MH  - Adjuvants, Vaccine
MH  - Adult
MH  - *Herpes Zoster/chemically induced/epidemiology/prevention & control
MH  - *Herpes Zoster Vaccine/adverse effects
MH  - Humans
MH  - Medical Records
MH  - *Rheumatic Diseases
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/06 06:00
MHDA- 2022/02/25 06:00
CRDT- 2021/10/05 12:19
PHST- 2021/10/06 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/10/05 12:19 [entrez]
AID - 00124743-202203000-00045 [pii]
AID - 10.1097/RHU.0000000000001790 [doi]
PST - ppublish
SO  - J Clin Rheumatol. 2022 Mar 1;28(2):e528-e531. doi: 10.1097/RHU.0000000000001790.